Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial.
Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial.
复制标题
DOI：
10.1017/s0007114515002950
复制
发表时间：
2015-10-28
期刊：
影响因子：
--
通讯作者：
Egert S
中科院分区：
文献类型：
--
作者：
Brüll V;Burak C;Stoffel-Wagner B;Wolffram S;Nickenig G;Müller C;Langguth P;Alteheld B;Fimmers R;Naaf S;Zimmermann BF;Stehle P;Egert S
多酚槲皮素由于其抗高血压和血管舒张特性可以预防心血管疾病。我们研究了定期摄入槲皮素对超重至肥胖的高血压前期和 I 期高血压患者血压 (BP) 的影响。此外，还探讨了槲皮素对血压的假设影响的潜在机制。在一项双盲、安慰剂对照交叉试验中，受试者 (n 70) 被随机接受 162 毫克/天的洋葱皮提取物粉末槲皮素治疗或安慰剂治疗，其中 6 周的治疗期与 6 周的清除期相隔。干预前后测量动态血压（ABP）和诊室血压；收集尿液和血液样本；采用EndoPAT技术测量内皮功能。在整个组中，槲皮素没有显着影响 24 小时 ABP 参数和诊室血压。在高血压亚组中，与安慰剂相比，槲皮素使 24 小时收缩压降低了 -3·6 mmHg (P=0·022)（平均治疗差异，-3·9 mmHg；P=0·049）。此外，槲皮素可显着降低高血压患者的白天和夜间收缩压，但在组间比较中没有显着效果。在整个组和高血压亚组中，血管活性生物标志物，包括内皮素-1、可溶性内皮源性粘附分子、不对称二甲基精氨酸、血管紧张素转换酶活性、内皮功能、氧化参数、炎症、脂质和葡萄糖代谢不受槲皮素影响。总之，每天补充 162 mg 洋葱皮提取物中的槲皮素可降低高血压患者的 ABP，表明槲皮素具有心脏保护作用。降压作用的机制仍不清楚。
The polyphenol quercetin may prevent CVD due to its antihypertensive and vasorelaxant properties. We investigated the effects of quercetin after regular intake on blood pressure (BP) in overweight-to-obese patients with pre-hypertension and stage I hypertension. In addition, the potential mechanisms responsible for the hypothesised effect of quercetin on BP were explored. Subjects (n 70) were randomised to receive 162 mg/d quercetin from onion skin extract powder or placebo in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 6-week washout period. Before and after the intervention, ambulatory blood pressure (ABP) and office BP were measured; urine and blood samples were collected; and endothelial function was measured by EndoPAT technology. In the total group, quercetin did not significantly affect 24 h ABP parameters and office BP. In the subgroup of hypertensives, quercetin decreased 24 h systolic BP by −3·6 mmHg (P=0·022) when compared with placebo (mean treatment difference, −3·9 mmHg; P=0·049). In addition, quercetin significantly decreased day-time and night-time systolic BP in hypertensives, but without a significant effect in inter-group comparison. In the total group and also in the subgroup of hypertensives, vasoactive biomarkers including endothelin-1, soluble endothelial-derived adhesion molecules, asymmetric dimethylarginine, angiotensin-converting enzyme activity, endothelial function, parameters of oxidation, inflammation, lipid and glucose metabolism were not affected by quercetin. In conclusion, supplementation with 162 mg/d quercetin from onion skin extract lowers ABP in patients with hypertension, suggesting a cardioprotective effect of quercetin. The mechanisms responsible for the BP-lowering effect remain unclear.